NitroMed's BiDil Approved For Heart Failure In Self-Identified Black Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
The hydralazine/isosorbide dinitrate combination is the first approval for a race-based indication. In its recent review of BiDil, an FDA advisory committee suggested race was serving as a surrogate for genomic markers. FDA suggests further study could expand BiDil's approval beyond self-identified black patients.
You may also be interested in...
NitroMed Looks To 2010 NDA For BiDil XR
Firm decides to slash jobs, quit promotion of immediate-release BiDil to fund development and commercialization of extended-release version.
NitroMed Looks To 2010 NDA For BiDil XR
Firm decides to slash jobs, quit promotion of immediate-release BiDil to fund development and commercialization of extended-release version.
NitroMed’s BiDil XR Will Use Elan Delivery Technology Under Recent Deal
Collaboration centers on use of Elan’s proprietary oral controlled-release delivery technology.